Clinical Trial Update: VA111913 Dysmenorrhoea Efficacy and Safety Proof of Concept [Phase 2]

View source ↗

Summary

Phase 2 trial VA111913 for primary dysmenorrhea has completed, presenting efficacy and safety proof-of-concept results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dysmenorrhea

Drugs mentioned

• VA111913 (VA111913)

Snippet

Sponsor: Vantia Ltd | Conditions: Primary Dysmenorrhea | Phase 2 | Status: COMPLETED